Blerp – Lifestyle
Author:
Classover Holdings Inc.
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 7, 2026
Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
May 5, 2026
Classover Announces Strategic Collaboration With Vensin Computer Technology To Advance AI Robotics Education and Infrastructure
May 4, 2026
Classover and Harvard-Incubated Marbella AI Announce Strategic Partnership to Advance AI Education
April 29, 2026
Classover Named to TIME’s America’s Top EdTech Companies of 2026
April 27, 2026
Classover Enters Strategic Collaboration with ICreate Education Technology to Advance AI Robotics Learning in North America
April 22, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
April 16, 2026
Classover and Luka Announce Strategic Collaboration to Advance AI-Powered Learning and Companion Robotics in North America
April 15, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026
Classover Announces Full Year 2025 Financial Results: Gross Margin Expands, Makes Strategic Advances in AI and Robotics
April 2, 2026
1
2
Next Page
→